Rhinoplasty is associated with intraoperative bleeding which affects the quality of operation and may increase surgery duration. This study is designed with the aim assessing the role of intravenous tranexamic acid (TA) on reduction of intraoperative bleeding during elective open rhinoplasty. This was a single center double blind randomized controlled trial (phase 2) conducted in Imam Khomeini Hospital affiliated to Ahvaz Jundishapur University of Medical Sciences, one hundred candidates of elective rhinoplasty were randomly allocated to one treatment arm receiving a bolus 10mg/kg dose of intravenous TA (n=50) and one control group being administered with normal saline as the placebo (n=50). All subjects underwent open rhinoplasty under general anesthesia with the same surgical team using standard technique. The primary outcome measure was the estimated volume of intraoperative bleeding (measured in mL). Ninety six patients successfully completed the study (n=48 in each group). Unadjusted for covariates, the total volume of blood loss was 43.3±11.0 mL in the TA group while it was 60.3±9.5 mL in the control group (mean difference=16.9 mL, 95% CI [12.7-21.0], p<0.001). After controlling for the confounding effect of age, gender, weight and surgery duration on intraoperative blood loss, TA was associated with a 15.6 mL decrease (95% CI [11.8-19.4], p<0.001) in intraoperative bleeding. Considering the efficacy and safe therapeutic profile of tranexamic acid, we recommend a single bolus dose of intravenous TA (10mg/kg) upon anesthesia induction in order to achieve satisfactory hemostasis in healthy candidates of open rhinoplasty.
INTRODUCTION
The modern sense of beauty has increased tremendously over the recent decade leading to high expectations of patients and the public belief that most of all facial deficiencies can be corrected. Therefore, rhinoplasty has become one of the common facial aesthetic surgeries worldwide and in Iran 1, 2 . Rhinoplasty performed with the aesthetic purposes outweighs that of the functional goals in Iran such that 35000 to 70000 procedures are carried out annually in Tehran (capital of Iran). However, the procedure is associated with periortbital edema, ecchymosis and specifically intraoperative bleeding which in turn increases surgery duration preventing the surgeon from attaining optimal aesthetic results, increasing the postoperative recovery period 3, 4 . Various preventive and therapeutic approaches have been proposed to reduce bleeding during rhinoplasty which include head elevation, cold compressions, administration of vasoconstrictive agents, intraoperative controlled hypotension and administration of pharmacologic hemostatic agents. Among the hemostatic agents, tranexamic acid (TA) is a synthetic derivative of the amino acid lysine, which serves as an antifibrinolytic agent preventing dissolution of the fibrin clot 5 . This agent is well known to reduce gynecologic bleeding such as heavy menstrual bleeding and postpartum hemorrhage. In addition, intravenous TA reduces preoperative blood loss in a variety of surgical procedures including cardiac surgery, total hip/knee replacement and prostatectomy [6] [7] [8] . However, in the case of facial surgery and specifically elective rhinoplasty, few studies have evaluated beneficial effects of TA on reducing perioperative bleeding. For instance, intravenous administration of TA (5-15 mg/Kg) significantly decreased hemorrhage during endoscopic nasal sinus surgeries 9, 10 . Regarding rhinoplasty, there is only one published trail showing that patients receiving either oral or intravenous TA, have lower intraoperative bleeding comparing to controls 11 . There appears to be enough evidence at present to justify a randomized trail assessing the role of intravenous TA on reduction of intraoperative bleeding during rhinoplasty surgery.
Patients and Methods

Study Design
This prospective randomized double blinded placebo controlled trail aims to understand whether intravenous administration of tranexamic acid (10 mg/kg) exceeds placebo in reducing intra operative amount of bleeding in patients undergoing elective open rhinoplasty. This parallel designed trial was conducted in Imam Khomeini Hospital (Ahvaz, Iran) from March 2014 to March 2015. All participants were asked to fill and sign the written consent after being informed about the study design and purpose. Thereafter, subjects were randomly allocated to one treatment arm receiving intravenous TA at a dose of 10 mg/kg immediately after anesthesia induction, and one control arm being administered with normal saline (10 mL) as the placebo. Open Rhinoplasty was performed using standard technique and estimated volume of intraoperative hemorrhage, was the primary outcome measure.
Participants
Individuals with the following criteria were considered eligible for inclusion: Normotensive patients scheduled for elective open rhinoplasty aged 16-42 years with ASA (American Society of Anesthesiologists) class of either I or II without a history bleeding diathesis. Subjects with the following characteristics were excluded: presence of a history of allergy or hypersensitivity to tranexamic acid, brain vascular diseases, coronary artery diseases, cardiac dysrhythmia, liver/kidney or metabolic disorders, ASA class of either III or IV. In the context of an interview upon the initial visit in outpatient ENT (Ear Nose and Throat) clinic affiliated to Ahvaz Jundishsapur University of Medical Sciences, baseline characteristics (age, gender, weight, previous medical history) were recorded during patient recruitment. Surgery duration, total amount of irrigation and number of blood soaked 4*4 gauzes were recorded by the anesthesiologist and reported after rhinoplasty was finished.
Interventions
Study subjects in the treatment arm were administered with a bolus intravenous dose of tranexamic acid (10 mg/kg Caspian -Tamin Pharmaceutical Company, Rasht, Iran) which was transfused slowly after anesthesia induction. Patients in the control group received normal saline as the placebo. Anesthesia was attempted similarly for all patients. Briefly, protocol 2 mg/kg and fentanyl 1 mcg/kg were transfused with the aim of induction. Atracurium (0.5 mg/kg IV) was administered to facilitate orotracheal intubation and anesthesia was maintained using isoflurane inspired at a flow rate of 5 L/min in combination with air 30% in oxygen. Intravenous neostigmine 0.04 mg/kg and atropine 0.01 mg/kg were used to reverse neuromuscular blockage at the end of operation. Extubation was attempted after recovery of adequate spontaneous ventilation and patients were transferred to post anesthesia care unit where additional recovery was monitored.
Outcomes
The primary outcome measure was the estimated amount of intraoperative bleeding measured in milliliters which was calculated as follows. The volume of blood suctioned during a surgery is calculated by subtracting the amount of irrigation fluid used during a surgery from the total amount of fluid gathered in suction canister at the end of surgery. The volume of blood absorbed by 4*4 inch gauzes during an operation is calculated by multiplying the number of gauzes completely soaked with blood by 10 milliliters (an estimated average of blood absorbed per gauze) 12 . These two values were then added to estimate the total intraoperative volume of blood loss. No secondary outcome measures were defined.
Sample Size and Randomization
Sample size was determined based on a priori analysis conducted on 20 patients which revealed the total amount of bleeding to be 42±12 mL for patients receiving TA, and 59±12 mL in the control group. Assuming a type I error of 0.05 (α) and a power of 0.95 (1-β), 20 patients were required in each group to detect a 25% difference in total volume of blood loss.
A statistician not otherwise involved in the study provided the randomization sequence using the Microsoft Excel program. One hundred random numbers were generated and printed. Allocation letters were sent to pharmacy unit where one investigator prepared TA or normal saline solutions so that they appeared indistinguishable to the case anesthesiologist and operating surgeon. The solution bags were sent to the operating room consecutively upon patients' arrival. This investigator was not involved in data gathering or analysis. The randomization scheme was not revealed until data was collected from all patients.
Statistical Analysis
Data management and analysis was conducted using the Statistical Package for Social Sciences (SPSS, version 18, Chicago, Illinois). Normality was checked using the Shapiro-Wilk test and normally distributed continuous variables were summarized using mean and standard deviation (Mean±SD). Categorical variables were summarized by frequencies and proportions [n (%)]. Upon initiation of inferential statistical testing, a two sided p-value of less than 0.05 was considered statistically significant. Comparison between TA and control groups was conducted using the independent t-test regarding baseline continuous variables and Pearson Chi-square test for baseline categorical variables. The total amount of bleeding was considered as a continuous variable (outcome) and independent t-test is used to compare average blood loss between the study groups. A multiple linear regression was used to control for possible confounding effect of age, gender, weight, surgery duration on the total amount of intraoperative bleeding.
RESULTS
A total number of 100 elective rhinoplasty candidates were randomly assigned to preoperative intravenous TA (n=50) or placebo (n=50). Figure 1 represents flow of patients throughout the study. In the TA group, two participants refused to take part in the trial after enrollment and another two canceled the surgery in the placebo group leaving 98 patients to undergo statistical analysis. The trail was commenced from March 2014 to March 2015. On bivariate analysis, intraoperative volume of bleeding was not correlated with participants' age (r=0.098, p=0.12). On average males had a higher amount of bleeding (56.6±12.4 mL) comparing to females (50.5±13.3 mL), however, this difference did not reach statistical significance (mean difference=6.1 mL, 95% CI [-0.4-12.7], p=0.07). The volume of blood loss was significantly but weakly correlated with subjects' weight (r=0.16, p=0.026). As expected, duration of rhinoplasty significantly affected the total amount of intraoperative bleeding (r=0.53, p<0.001).
Unadjusted for covariates, the total volume of blood loss was 43.3±11.0 mL in the TA group while it was 60.3±9.5 mL in the control group (mean difference=16.9 mL, 95% CI [12.7-21 .0], p<0.001). A Multiple linear regression analysis was conducted to control for possible confounding effects of age, gender, weight and surgery duration on intraoperative blood loss. The model adequately fitted the data (F [5, 90] =26.8, p<0.001, R2=0.60). In this model, tranexamic acid was associated with a 15.6 mL decrease (95% CI [11.8-19.4 ], p<0.001) in intraoperative bleeding after adjusting for confounders (Table-2 ).
DISCUSSION
During the recent years, there has been a consistent increasing demand for cosmetic facial surgeries, specifically rhinoplasty. Surgeons may be encountered with cases of considerable bleeding which may hinder surgical field eventually leading to misidentifications of anatomic structures and undesired surgical outcome. Various methods have been proposed with aim of controlling intraoperative bleeding which include preparing the nose with local vasoconstrictors, use of hypotensive anesthesia, and elevating the head of the bed during surgery. Meanwhile, tranexamic acid has a proven effect in various surgeries 13 and this study was developed to determine if tranexamic acid had any impact on intraoperative bleeding during open rhinoplasty.
In this trial, 98 candidates of open rhinoplasty were randomized to receive preoperative intravenous tranexamic acid or placebo. To reduce the effect of confounding factors, all operations were performed by the same surgical team using the same technique. In addition, patients with uncontrolled hypertension were excluded in order to achieve a homogenous population which helped to maintain a standardized anesthetic protocol to remove intraoperative blood pressure as a confounding variable. Since therapeutic concentration of TA is maintained for approximately three hours 14 , a single intravenous bolus dose of 10 mg\kg was assumed to satisfyingly fulfil our therapeutic intention. Considering the average duration of rhinoplasty which was less than 1 hour (54.6±6.0 minutes) in this study, we assume that an acceptable TA blood level is achieved without directly measuring its serum levels. Meanwhile, other researchers has shown that administration of 15 mg/Kg TA intravenously is more effective than 5 mg or 10 mg in achieving hemostasis and improving the quality of surgical field during endoscopic sinus surgery without considerable adverse effects (9).
Our findings indicated that on average, tranexamic acid decreased intraoperative bleeding by 15.6 mL. This hemostatic effect was also evident after controlling for patients' demographics and duration of operation. Our results could be regarded as another piece of evidence confirming a preventive role of tranexamic acid in reducing intraoperative bleeding. It should be mentioned that the hemostatic property of tranexamic acid was affected by patients' gender, weight and surgery duration. This implies that female patients with higher weight and longer rhinoplasty duration may benefit this treatment the least. To the best of our knowledge and specifically in case of rhinoplasty, there is only one published study by Sakallioðlu, which showed that administration of oral tranexamic acid (one gram, 2 hrs before surgery) is associated with significantly less intraoperative bleeding compared with placebo 11 . Apart from rhinoplasty surgery, various authors have documented the hemostatic effect of TA during endoscopic sinus surgeries. In a study conducted by Alimian et al. on patients undergoing functional endoscopic sinus surgery, intravenous tranexamic acid (10 mg/kg) effectively reduced bleeding and improved the surgical field quality 15 . In a similar group of patients, a single (15 mg/kg) perioperative dose of TA significantly decreased hemorrhage without increasing side effects such as alteration in coagulation parameters, hemodynamic changes or emesis 16 . In addition, TA administered via others routs (topical/oral) has been shown to effectively reduce intraoperative bleeding during endoscopic nasal sinus surgeries [17] [18] [19] . Apart from the hemostatic properties, edema and ecchymosis following rhinoplasty is decreased using tranexamic acid 11 .
Results of the present study are not in agreement with findings of a more recent trail conducted by Langille et al., 20 . Although they used a relatively high bolus dose of intravenous TA (15 mg/kg) which was followed by TA infusion at a rate of 1 mg/kg/hr, TA did not appear to result in a clinically meaningful reduction in blood loss or improve visualization of the surgical field. This may have originated from the fact that different methods of estimating intraoperative bleeding are used and relatively lower number of subjects were studied in the referenced article (n=23). Finally, in a recent review of the role of tranexamic acid in endoscopic sinus surgeries, intra-operative use of local and systemic tranexamic acid resulted in significantly reduced estimated blood loss and improved surgical field quality. Moreover, operative time and incidence of side effects were not increased 10 . According to findings of the present work along with those existing in literature, it is concluded that wellconducted larger RCTs focusing on patients undergoing rhinoplasty are required to confirm the effect of TA on bleeding during surgery.
One major limitation of this study is that we did not address the quality of surgical field during rhinoplasty. Considering the fact that the average blood loss is less than 400 mL in the majority of nasal surgeries (50 ml in the present study), the bleeding itself may not be a considerable challenge, and rather it is the surgical field visualization that is of greater importance for a surgeon. We did not systematically monitored the studied subjects for possible adverse effects of intravenous TA or incidence of postoperative bleeding, though we did not encounter any major side effects.
CONCLUSION
Considering the efficacy and safe therapeutic profile of tranexamic acid, we recommend a single prophylactic dose of (10 mg/ kg) in healthy candidates of open rhinoplasty in order to reduce intraoperative bleeding.
